Sequential follow up observations of a patient with rubella associated persistent arthritis

D K Ford, G D Reid, A J Tingle, L A Mitchell, M Schulzer

Abstract
In 1985 a patient was described whose persistent polyarthritis was found to be aetiologically linked to rubella virus infection through the detection of repeated maximal synovial lymphocyte proliferative responses to rubella virus antigen and by isolation of rubella virus from her synovium. Follow up over the succeeding seven years has shown continuing chronic polyarthritis and persistent synovial lymphocyte responses to rubella virus antigen with the additional observation that she has a defective humoral immune response against rubella virus.

For many years rubella virus has been aetiologically linked to a syndrome of acute polyarthritis occurring particularly in adult women and generally of an acute, self limited nature. Less often, the syndrome may proceed to recurrent or persistent polyarthritis or arthralgia. Although the acute manifestations of rubella associated arthritis have been well studied, the chronic or recurrent features have been less well recognised or recorded. This paper outlines the clinical and immunological features over a seven year follow up period in a patient previously reported to have chronic arthritis associated with persistent rubella virus infection in synovial tissues and a persistently increased synovial lymphocyte proliferative response to rubella virus.

Case report
CLINICAL OBSERVATIONS
Table 1 summarises the clinical features of this patient. For the past 19 years she has had a persistent inflammatory polyarthritis, which has not been associated with rheumatoid factor nor rheumatoid nodules. Radiographs of her hands and knees showed some secondary degenerative changes, moderate osteopenia, and also uniform narrowing of the articular cartilage of the carpal bones in the left wrist (fig 1). In addition to polyarthritis the patient had an episode of thyroiditis in 1973, and two episodes of ureteric obstruction due to retroperitoneal fibrosis in 1978 and 1986. Medical treatment of her arthritis was complicated by uraemic episodes and moderate hypertension, so that for the past few years treatment had been restricted to enteric coated chlorazanil hydrochloride, low dose prednisone by mouth, and repeated intra-articular corticosteroid injections. She has been able to play a limited ‘twilight’ golf intermittently up to the present time.

\( ^3\text{H} \) LYMPHOCYTE STIMULATION ASSAY
The methodology used was the same as described previously. Ficoll Hypaque separated synovial lymphocytes, at 10 000 per well, were incubated in Terasaki plates for seven days in RPMI medium supplemented with 10% human AB plasma and containing the antigen to be tested, with multiple identical control unstimulated cultures being included in all tests. Standard harvesting methods followed exposure of the cultured lymphocytes to \(^{3}\text{H}\)thymidine, 37 kBq per well for four to six hours. All antigens were crude preparations because it was not known which of the various antigens were relevant. The methods of preparation of the ureaplastic, chlamydial, candida, salmonella, and other enteric antigens have been described previously. The viral antigens have also been described and were obtained from Microbiological Associates as the complement fixing antigen, except that up to 1987 the rubella antigen was obtained from Flow Laboratories. In 1989 and 1990, two additional viral antigens were routinely included: Herpesvirus hominis and a trivalent influenza A, B, C, antigen, also obtained from Microbiological Laboratories.

<table>
<thead>
<tr>
<th>Date (years)</th>
<th>Clinical manifestations and findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>1959 41</td>
<td>Contracted fever, malaise, rash, and enlarged cervical glands from son aged 12; considered to be rubella, but no medical observation and no complications</td>
</tr>
<tr>
<td>1971 53</td>
<td>Onset of recurrent subacute arthritis of both knees</td>
</tr>
<tr>
<td>1973 55</td>
<td>Diagnosed as having Hashimoto’s thyroiditis; treated with thyroxine and subsequently had no further thyroid problems</td>
</tr>
<tr>
<td>1976 58</td>
<td>Treated by a rheumatologist for recurrent variable arthritis of both knees</td>
</tr>
<tr>
<td>1978 60</td>
<td>Became uraemic and was diagnosed as having retroperitoneal fibrosis with ureteric obstruction; was treated successfully by abdominal surgery and prednisone</td>
</tr>
<tr>
<td>1980 62</td>
<td>Came under treatment by a second rheumatologist (GDR), who has followed her up over the subsequent ten years, during which variable subacute to chronic inflammatory arthritis of knees, elbows, wrists, ankles, and several finger proximal interphalangeal joints has persisted, without rheumatoid nodules and without rheumatoid factor</td>
</tr>
<tr>
<td>1983 65</td>
<td>Synovial lymphocyte studies showed maximum stimulation by rubella antigen, compared with 17 other microbiological antigens; consequent virological investigations showing rubella virus in synovial fluid, as reported previously</td>
</tr>
<tr>
<td>1986 68</td>
<td>Right nephrectomy and ureteric reimplantation for recurrence of retroperitoneal fibrosis</td>
</tr>
<tr>
<td>1990 72</td>
<td>Most recent observations show continued variable polyarthritis of the same joints, with the knees causing most functional disability and requiring repeated corticosteroid injections during exacerbations; radiographs of the hands are shown in fig 1.</td>
</tr>
</tbody>
</table>
Antigens. In 1990 tuberculin and a parvovirus antigen were used. The tuberculin was obtained from Connaught Laboratories as PPD Tubersol 250, and added to the cultures in six threefold dilutions to give from 8·3 to 0·03 units per well. The parvovirus antigen was supplied as the B 19 capsid antigen prepared from the 3-11-5 Chinese hamster ovary cell line, and diluted to give 0·5, 1·6, and 5 ng per Terasaki well. All antigens were routinely used in three serial threefold dilutions (1/3, 1/9, 1/27), and initially triplicate, but since 1989 quadruplicate, replicates were set up for each antigen dilution.

Data are shown as the mean of the counts per minute obtained from the antigen dilution giving the maximum response, the mean counts per minute of the unstimulated synovial lymphocytes being included in the barographs. The data were previously expressed as stimulation indices. The triplicate or quadruplicate counts per minute of the maximum antigen response were compared with those of the next highest response using the two tailed t test. In fig 2 an asterisk shows the responses with p values <0·05.

Figure 2 shows the [3H]thymidine uptake counts in response to antigenic stimulation by 22 microbiological antigens, observed in 16 evaluations over a seven year period from 1983 to 1990. Counts derived from unstimulated (control) synovial lymphocytes are shown in the left hand column. The response to rubella antigen was greatest in 13 of the 16 studies and, on five occasions, the application of the two tailed t test to the replicate counts of the rubella response versus the second highest antigen responses gave p values <0·05, as indicated by the asterisk in the rubella columns.

In 1983 and 1984 the synovial lymphocytes also responded to cytomegalovirus, but the response disappeared in later years. From 1988 to 1990 a herpes simplex antigen was included in the testing and synovial lymphocytes were clearly stimulated by this antigen; however, in the three most recent tests the rubella response was statistically greater. In 1990, testing against PPD Tubersol and a parvovirus antigen was performed, but no significant responses were detected.

MEASUREMENT OF ANTIBODY TO RUBELLA ANTIGENS
Antibodies of the IgG class directed to whole rubella virus, rubella virus major structural proteins (the envelope glycoproteins E1 and E2, and capsid protein, C) and an antigenic subregion of E1 represented by a synthetic peptide were measured by enzyme linked immunosorbent assay (ELISA) or immunoblot techniques as described in the following section.

Whole rubella virus ELISA assays were performed as described previously. Briefly, rubella virus (M33 strain) harvested from Vero cell culture and resuspended in 0·5% Triton X 100 in phosphate buffered saline (PBS, pH 7·2-7·4) was optimally diluted in 0·1 mol/l carbonate buffer (pH 9·6) and coated onto ELISA microplates by overnight incubation at 4°C. After washing the plates in PBS containing 0·5% Tween 20 (PBST), dilutions of serum from the patient or of reference standard serum were added to the wells and incubated at 37°C for one hour to allow specific antibodies to adhere to the viral proteins. After washing the plates with PBST, bound specific antibodies were detected by the addition of alkaline phosphatase conjugated goat antihuman IgG (Fc specific) followed by one hour of incubation at 37°C. After washing the plates with PBST,
enzyme substrate (o-nitrophenyl phosphate, 2·5 mg/ml in diethanolamine buffer, pH 9·8) was added to the wells and the plates incubated at 37°C until the colour development was optimal. After stopping the enzymatic reaction by adding 3 mol/l sodium hydroxide to the wells, the absorbance at 405 nm (A405) was determined on a microplate reader. Antibody levels in patient samples were determined by linear regression analysis from a standard curve of A405 versus the concentration of the reference standard serum sample. The results are expressed in IU/ml.

Neutralisation domain peptide ELISA values were determined using ELISA microplate wells coated with a synthetic peptide thought to represent a neutralisation domain on the rubella virus E1 protein (M. Zrein, IAF BioChem International, personal communication). Peptide coated microplate wells were subsequently exposed to 1:50 dilutions of patient or reference (15 IU/ml) or positive and negative control serum samples and incubated for 30 minutes at room temperature. After washing the plates with PBST, bound specific antibodies were detected by the sequential addition of horseradish peroxidase conjugated antihuman IgG antisera and enzyme substrate (tetramethylbenzidine/hydrogen peroxide) with 30 minute incubations and washing with PBST between the addition of the anti-human IgG antibody and substrate. After stopping the reaction by the addition of 1M HCl, A450 was determined for each well using a microplate reader. Levels of peptide specific antibody in patient samples were calculated as:

\[
\text{Antibody (IU/ml)} = \frac{A_{450 \text{ patient sample}}}{A_{450 \text{ reference}}} \times 15 \text{ IU/ml}
\]

The results are expressed in IU/ml.

Immunoblot assays were performed as described by Towbin et al.\(^3\) Briefly, purified rubella virus (M33) was electrophoretically separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis under non-reducing conditions. The separated proteins were transferred electrophoretically onto nitrocellulose membranes which were then blocked by incubation with 2% milk powder in PBS. The membranes were exposed to dilutions of patient serum or negative and positive control serum samples and washed in PBS containing 0·5% Tween 20. Bound specific antibodies were detected by the sequential addition of alkaline phosphatase conjugated goat antihuman IgG, followed by washing in PBS-Tween, and incubation with enzyme substrate (nitroblue tetrazolium/5-bromo-4-chloroindolyl phosphate in TRIS buffer, pH 9·5). Specific antibodies were detected by the appearance of a coloured band in the molecular weight range anticipated for the E1, E2, or C proteins, as observed on membranes incubated with positive control serum samples.

**Antibody Responses to Rubella Virus**

Table 2 summarises the humoral immune responses to rubella virus measured over the last three years of the follow up period. In general, IgG antibody levels measured by whole rubella virus ELISA in serum or plasma samples paralleled those measured in synovial fluid samples collected at the same time. All values were well above the established minimum protective levels of 15 IU/ml, although a progressive decline in antibody levels was observed over the time period studied.

In sharp contrast, levels of antibody measured by the neutralisation domain peptide ELISA were low, being below or barely above those measured in the negative control samples. Although protective antibody levels have not
yet been established for this new test, we have observed (Mitchell et al, unpublished data) similarly decreased levels of peptide antibody reactivity in patients with congenital rubella infection or syndrome, patients with rubella associated arthritis, and in patients failing to respond to rubella immunisation. This pattern of decreased peptide reactivity is markedly different from that observed in normal subjects responding to wild rubella infection or rubella vaccination, in whom the levels of peptide reactive antibody are observed to increase in parallel with antibodies reactive with whole rubella virus in ELISA, neutralisation, and haemagglutination inhibition assays (Mitchell et al, unpublished data). Hence the failure to develop antibodies to the neutralisation domain peptide observed in this patient may have some relevance to her clinical condition.

Selected plasma and synovial fluid samples examined by IgG immunoblot assay showed similar reactivities, with strong banding patterns with E1 and E2 but no reactivity with C protein. Although the intensity of the observed bands was greater than that usually observed with specimens from patients with uncomplicated infections showing similar levels of rubella specific antibody by ELISA, the importance of this observation is not known. Taken together with the observation of low peptide antibody reactivity, the immunoblot pattern suggests that the patient is able to make antibodies directed to antigenic subregions of E1 other than that represented in the synthetic peptide. Whether these antibodies include species directed to other neutralisation domains of the viral envelope proteins remains to be studied.

Table 2 Antibody responses to rubella virus

<table>
<thead>
<tr>
<th>Date of study</th>
<th>Whole rubella IgG ELISA</th>
<th>E1 peptide IgG ELISA</th>
<th>Rubella IgG immunoblot</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Serum sample</td>
<td>Synovial fluid sample</td>
<td>Serum sample</td>
</tr>
<tr>
<td>18 March 1987</td>
<td>123.4</td>
<td>84.7</td>
<td>ND</td>
</tr>
<tr>
<td>6 August 1988</td>
<td>126.4</td>
<td>111.6</td>
<td>ND</td>
</tr>
<tr>
<td>27 June 1989</td>
<td>98.7</td>
<td>141.9</td>
<td>ND</td>
</tr>
<tr>
<td>6 October 1989</td>
<td>65.5</td>
<td>75.4</td>
<td>ND</td>
</tr>
<tr>
<td>23 April 1990</td>
<td>72.3</td>
<td>88.9</td>
<td>1.2</td>
</tr>
<tr>
<td>23 July 1990</td>
<td>28.0</td>
<td>13.2</td>
<td>2.4</td>
</tr>
</tbody>
</table>

*Results given as IU/ml. Negative <15 IU/ml.†Results given as IU/ml. Negative <15 IU/ml.‡ND = not done.

Discussion

Previous reports have aetio logically linked rubella virus to syndromes of acute and recurrent or persistent polyarthritis. This case report documents the long term clinical and immunological follow up of one patient reported to have rubella associated arthritis on the basis of the persistent infection of synovial tissues with rubella virus and evidence of persistent maximal proliferative responses of synovial lymphocytes to rubella virus.

Follow up observations of this patient have therefore shown the persistence of her chronic inflammatory polyarthritis for 19 years, and also the persistence of her maximum synovial lymphocyte reactivity to rubella antigen over a period of seven years.

Screening tests for total rubella specific antibody (whole rubella virus IgG ELISA) showed low to moderate levels of specific antibody in serum and synovial fluid. Antibody responses directed to each of the three major structural proteins of rubella virus, E1, E2, and C were assessed by immunoblotting, which detected the presence of specific IgG directed against the envelope glycoproteins (E1 and E2) but none against capsid protein (C). Identical patterns of reactivity were observed in serum and synovial fluid. Of particular interest in this patient was the extremely low levels of antibody reactive with a synthetic peptide which may represent a neutralisation domain on rubella virus E1 protein. The absence of detectable antibody by this technique, despite the observation of levels of antibody directed to other rubella virus structural proteins as shown by immunoblot, suggests that the patient may have been unable to mount a protective serological response to rubella virus and that a defective immune response may have contributed to the establishment of rubella virus persistence in this subject. It is expected that the further development of antigen specific immunological techniques will clarify the pathogenesis of the arthritis and its relation to rubella infection.

This work was supported by funds provided by the Mary Pack Fund, the Beta Sigma Phi, Bill and Betty McQueen, Medical Research Council of Canada. The parovirus antigen was kindly supplied by Dr Collett, Molecular Vaccines Inc, Gaithersburg, MD, USA.

Sequential follow up observations of a patient with rubella associated persistent arthritis.

D K Ford, G D Reid, A J Tingle, L A Mitchell and M Schulzer

doi: 10.1136/ard.51.3.407